de Vega, Wilfred C, Vernon, Suzanne D, McGowan, Patrick O · PloS one · 2014 · DOI
This study looked at chemical tags attached to DNA (called methylation) in the blood cells of people with ME/CFS compared to healthy people. The researchers found that people with ME/CFS have differences in these chemical tags on genes related to immune function, energy production, and cell signaling. These differences might help explain why the immune system and energy systems aren't working properly in ME/CFS.
This is the first genome-wide methylation study in ME/CFS, providing molecular evidence that abnormal gene regulation—not just genetic mutations—may drive disease pathology. Understanding epigenetic changes could eventually lead to diagnostic biomarkers and new therapeutic targets, and suggests that ME/CFS has a biological basis at the molecular level.
This study does not prove that DNA methylation changes cause ME/CFS—it only shows they are associated with the disease, and causality remains unclear. It does not establish whether these methylation patterns are primary disease drivers or secondary consequences of chronic illness. The findings require functional validation to demonstrate that these epigenetic changes actually alter gene expression and immune dysfunction.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.